Shares of uniQure N.V. (NASDAQ:QURE – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $56.64.
Several equities analysts recently weighed in on the stock. William Blair upgraded shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group dropped their target price on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research report on Wednesday. HC Wainwright reissued a “buy” rating on shares of uniQure in a research note on Tuesday. Mizuho raised their price target on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, Leerink Partners lifted their price objective on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th.
View Our Latest Report on uniQure
uniQure Price Performance
uniQure (NASDAQ:QURE – Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business posted ($0.69) EPS. As a group, research analysts anticipate that uniQure will post -3.82 earnings per share for the current year.
Hedge Funds Weigh In On uniQure
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC grew its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the period. Orbimed Advisors LLC raised its position in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the period. Artia Global Partners LP raised its position in shares of uniQure by 55.4% in the 4th quarter. Artia Global Partners LP now owns 1,023,539 shares of the biotechnology company’s stock valued at $24,493,000 after acquiring an additional 364,700 shares during the period. Assenagon Asset Management S.A. raised its position in shares of uniQure by 249.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock valued at $23,653,000 after acquiring an additional 366,781 shares during the period. Finally, Fiera Capital Corp bought a new position in uniQure during the 4th quarter worth approximately $18,390,000. Institutional investors own 78.83% of the company’s stock.
About uniQure
uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.
uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.
See Also
- Five stocks we like better than uniQure
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
